Strategies for prevention of toxicity caused by platinum-based chemotherapy: Review and summary of the annual meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, March 10, 2001

Brian W. Blakley, James I. Cohen, Nancy D. Doolittle, Leslie L. Muldoon, K. C. Campbell, D. Thomas Dickey, Edward A. Neuwelt

Research output: Contribution to journalArticle

51 Scopus citations

Abstract

Objectives: To summarize the findings relevant to otolaryngology from the annual meeting of the Blood-Brain Barrier Disruption Consortium in Gleneden Beach, Oregon, March 10, 2001. Study Design: Summaries are provided by the speakers, as well as related data from the published literature. Findings in otology and oncology regarding ototoxicity that were discussed at the meeting are included. Results: Data considered included physiological research, animal studies, and clinical trials that relate to platinum-based chemotherapy and prevention of toxicity. Conclusions: The dose-limiting side effects of platinum-based chemotherapy are preventable, but questions about the effect of the protective agents on oncological efficacy remain. Strategies for prevention of chemotherapy-induced toxicity include temporal or anatomical separation of cisplatin or carboplatin from sodium thiosulfate, D-methionine, or N-acetyl-cysteine. Clinical application of these methods has begun. The mechanisms presumably involve free radicals or drug conjugation, or both. Understanding the role of free radicals in medicine is likely to become important in the future.

Original languageEnglish (US)
Pages (from-to)1997-2001
Number of pages5
JournalLaryngoscope
Volume112
Issue number11
DOIs
StatePublished - Nov 1 2002

Keywords

  • Blood-brain barrier
  • Ototoxicity
  • Platinum-based chemotherapy
  • Sodium thiosulfate protection

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'Strategies for prevention of toxicity caused by platinum-based chemotherapy: Review and summary of the annual meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, March 10, 2001'. Together they form a unique fingerprint.

  • Cite this